Immunocore/$IMCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immunocore
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Ticker
$IMCR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
493
ISIN
US45258D1054
Website
Immunocore Metrics
BasicAdvanced
$1.6B
-
-$0.43
0.75
-
Price and volume
Market cap
$1.6B
Beta
0.75
52-week high
$41.54
52-week low
$23.15
Average daily volume
512K
Financial strength
Current ratio
6.36
Quick ratio
6.034
Long term debt to equity
114.215
Total debt to equity
114.668
Interest coverage (TTM)
-1.59%
Profitability
EBITDA (TTM)
-25.489
Gross margin (TTM)
113.90%
Net profit margin (TTM)
-6.48%
Operating margin (TTM)
-8.85%
Effective tax rate (TTM)
5.03%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
-1.83%
Return on equity (TTM)
-5.86%
Valuation
Price to revenue (TTM)
4.756
Price to book
4.2
Price to tangible book (TTM)
4.2
Price to free cash flow (TTM)
61.939
Free cash flow yield (TTM)
1.61%
Free cash flow per share (TTM)
51.18%
Growth
Revenue change (TTM)
25.75%
Earnings per share change (TTM)
-64.64%
3-year revenue growth (CAGR)
85.08%
3-year earnings per share growth (CAGR)
-50.18%
What the Analysts think about Immunocore
Analyst ratings (Buy, Hold, Sell) for Immunocore stock.
Bulls say / Bears say
Immunocore's KIMMTRAK achieved net revenues of $93.9 million in Q1 2025, marking a 33% year-over-year growth, indicating strong market adoption and potential for continued revenue expansion. (stocktitan.net)
The company maintains a robust cash position of $837.0 million as of March 31, 2025, providing substantial financial flexibility to support ongoing research and development initiatives. (stocktitan.net)
Immunocore is advancing multiple Phase 3 trials across various melanoma indications, with initial data readouts expected in 2026, potentially expanding its product portfolio and market reach. (stocktitan.net)
In Q1 2025, Immunocore reported a net income of $5.0 million, a significant improvement from a net loss of $24.4 million in the same period in 2024, but the company has a history of operating losses, which may raise concerns about consistent profitability. (stocktitan.net)
The company's research and development expenses increased to $214.38 million in FY 2024 from $157.08 million in FY 2023, reflecting a substantial rise that could pressure financial resources if not offset by revenue growth. (stockanalysis.com)
Immunocore's operating margin remains negative at -16.90% as of FY 2024, indicating ongoing challenges in achieving operational profitability. (stockanalysis.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Immunocore Financial Performance
Revenues and expenses
Immunocore Earnings Performance
Company profitability
Immunocore News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immunocore stock?
Immunocore (IMCR) has a market cap of $1.6B as of June 20, 2025.
What is the P/E ratio for Immunocore stock?
The price to earnings (P/E) ratio for Immunocore (IMCR) stock is 0 as of June 20, 2025.
Does Immunocore stock pay dividends?
No, Immunocore (IMCR) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Immunocore dividend payment date?
Immunocore (IMCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunocore?
Immunocore (IMCR) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.